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Objective: To investigate the expression of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of
metallopropteinase-1 (TIMP-1) in the renal allografts of patients with chronic active antibody-mediated rejection
(AMR), and to explore their role in the pathogenesis of AMR.
Methods: Immunohistochemistry assay and computer-assisted image analysis were used to detect the expression
of MMP-2 and TIMP-1 in the renal allografts with interstitial fibrosis and tubular atrophy (IF/TA) in 46 transplant
recipients and 15 normal renal tissue specimens as the controls. The association of the expression level of either
MMP-2 or TIMP-1 with the pathological grade of IF/TA in AMR was analyzed.
Results: The expression of either MMP-2 or TIMP-1 was significantly increased in the renal allografts of the
recipients as compared with the normal renal tissue (P < 0.05). MMP-2 expression tended to decrease, while TIMP-1
and serum creatinine increased along with the increase of pathological grade of IF/TA (P < 0.05). In IF/TA groups,
the expression of TIMP-1 was positively correlated to serum creatinine level (r = 0.718, P < 0.05).
Conclusions: It is suggested by the results that abnormal expressions of MMP-2 and TIMP-1 might play roles in the
development of renal fibrosis in chronic AMR.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1128474926172838
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C4d was found to sedimentate in peritubular capillaries in
renal allografts in 1993. Since then it was looked as a sen-
sitive indicator to detect humoral rejection and was
included in Banff 07 pathologic diagnostic criteria, there-
fore chronic active antibody-mediated rejection (AMR)
was being paid more and more attention [1]. However the
exact pathogenesis of that was not full elucidated. Renal
fibrosis, including renal interstitial fibrosis and glomerular
sclerosis, is the common pathological mechanism of various
chronic kidney diseases including chronic renal allograft
dysfunction (CRAD) resulted from AMR, and finally* Correspondence: hequnzou@hotmail.com
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reproduction in any medium, provided the ordevelops into end-stage renal disease (ESRD). Previous
studies suggest that matrix metalloproteinase-2 (MMP-2)
and tissue inhibitor of metalloproteinase-1 (TIMP-1)
were important cytokines for extracellular matrix (ECM)
synthesis and degradation, and the excess accumulation
of ECM is the main pathological mechanism of fibrosis.
So we studied the relationship of MMP-2 and TIMP-1
with renal interstitial fibrosis in renal allografts.Methods
Patients
The renal biopsy samples were collected from kidney
transplant patients with proteinuria and elevated serum
creatine level from January 2006 to December 2010 in
Guilin No.181 Hospital. 46 patients with clinical diagno-
sis of chronic allograft dysfunction were diagnosed as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and 14 were females (age 42 ± 8 years). The duration
after kidney transplantation were 1-9 years (mean time
of 3.5 years), the mean level of serum creatine was
346.93 ± 178.37 μmol/, 24h urinary protein >0.5g/24h and
urinary protein (1+ - 4+). The triple immunosuppressant
treatment protocol was cyclosporine +mycophenolate
mofetil + prednisone in 28 patients and tacrolimus +
mycophenolate mofetil + prednisone in 17 patients and
sirolimus +mycophenolate mofetil + prednisone in 1
patient. Before renal biopsy, color doppler ultrasound
detection in renal allografts and serum drug concentra-
tion test were performed to exclude acute rejection,
nephrotoxicity of immunosuppressant, obstruction/
reflux of ureter, thrombosis or embolism in renal arteries
or veins and other diseases. According to Banff 2007
[2] renal allograft pathological classification criteria,
patients with positive C4d deposit in renal allograft
were diagnosed as AMR. The donor and recipient
were matched in ABO blood groups and two or more
HLA antigens were matched. The result of lymphocy-
totoxicity test was less than 10% and the result of
panel reaction antibody (PRA) was negative. The renal
samples of 15 cases of control were collected from
routine donor kidney biopsy before transplantation and
there was no pathological manifestation. Informed con-
sents were obtained from all patients that participated
in the study. Informed consents were obtained from
all patients that participated to the study. This study
was performed under the supervision of Institutional
Review Board of Southern Medical University, and
abided the Helsinki Declaration on ethical principles
for medical research involving human subjects.
Pathological classification
According to Banff 09 [2] renal allograft pathological diag-
nostic classification criteria, patients with C4d positive
(linear deposit of C4d in 50% peritubular capillary) were
diagnosed as AMR. All of the recipients were divided into
three groups (IF/TA-I, IF/TA-II and IF/TA-III) according
to the Banff 09 pathological diagnostic classification stand-
ard based on the degree of interstitial fibrosis of allograft
tissue: IF/TA-I group including 16 patients with mild
interstitial fibrosis and renal tubular atrophy (less than 25
percent renal cortex was involved); IF/TA-II group includ-
ing 14 patients with moderate interstitial fibrosis and renal
tubular atrophy (26 percent to 50 percent renal cortex
was involved); IF/TA-III group including16 patients with
severe interstitial fibrosis and renal tubular atrophy (more
than 50 percent renal cortex was involved).
Immunohistochemisty examination of MMP-2 and TIMP-1
Immunohistochemisty assay with EnVision was used to
detect the expression of MMP-2, TIMP-1 and C4ddeposit in the renal allograft tissue. Sections of 3-μm-
thick tissue were hydrated through graded ethanol, and
endogenous peroxidase was blocked with 3% peroxide
hydrogen. For MMP-2 test the section was treated with
microwave for 15 minute, however for TIMP-1 test the
section was treated with 10mmol/L of pH6.0 citrate buf-
fer solution. The section was incubated respectively with
each of the primary antibodies (mouse anti-human
MMP-2 monoclonal antibody, 1:200, Maixin Biological
Technology Development Co. Fujian, No. MAB-O244;
rabbit anti-human TIMP-1 polyclonal antibody, working
solution, Maixin Biological Technology Development
Co. Fujian, No. RAB-0282; rabbit anti-human C4d poly-
clonal antibody, working solution, Santa Cruz, No. RAB-
02415) overnight at 4°C. After washing with PBS 3 × 3
min, then incubated with second antibody (rabbit anti-
mouse monoclonal antibody, Maixin Biological Technology
Development Co. Fujian) for 30 min at 37°C, and then
washed with PBS 3 × 3min. Then the sections were treated
with DAB coloration and re-stained with hematoxylin.
Image semi-quantitative analysis
Images were acquired by means of Leica DMR-X micro-
scope coupled to a Leica DC500 digital camera (Leica,
Wetzlar, Germany) and the image analysis system Quan-
timet Q550 (Leica Imaging Systems). Ten randomly
selected discontinuous fields (400x) per kidney were
evaluated, including tubulointerstitial in renal cortex,
medulla and the conjunction region, (but not including
glomulular and vessels). More than 60 tubules in each
biopsy section were obeserved. The positive area was
yellow staining and Image-Pro Plus software was used to
quantify the integrated optical density. The ratio of posi-
tive area to total tubulointerstitial area (not including
the area of tubular lumens) presented the relative
amount of the substance expression in tubuloinstitium.
Statistical analysis
Results were expressed as means ± SD. Statistical ana-
lysis was performed with SPSS 13.0 (SPSS, Chicago, IL).
Measurement data was analyzed with one way ANOVA,
and the relationship was analyzed with Spearman rank
correlation. Statistic significance was set at P < 0.05
level.
Results
Expression of MMP-2 and TIMP-1
MMP-2 and TIMP-1 were mainly expressed in renal
tubular epithelial cells, renal tubular basement mem-
brane and cytoplasm of interstitial cells, looking like pale
yellow, pale brown and russet particals as positive. There
was no or rare expression of MMP-2 and TIMP-1 in
normal kidney tissue, but there was significant expres-
sion of MMP-2 and TIMP-1 in AMR groups, mainly in
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MMP-2 was expressed to the most in IF-TA group, but
decreased with the aggravation of mesenchyme disorder.
However the expression of TIMP-1 increased with the
aggravation of mesenchyme disease (Figures 1, 2, 3, 4, 5,
6, 7, 8). Expression of MMP-2 and TIMP-1 in tubular
interstitial cell increased significantly in AMR groups
compared to normal group, there was significant differ-
ence (P < 0.001), and expression of MMP-2 was decreaing
with the increase of IF/TA pathological classification
(P < 0.05), expression of TIMP-1 was increaing with the
increase of IF/TA pathological classification (P < 0.05,
Table 1).Figure 2 MMP-2 expression in renal tissue with different
degree of inflammatory infiltration(EnVision assay; original
magnification × 200). IF/TA-I Group.Expression of C4d
Rare C4d deposits were found in endothelial cell and/or
basal membrane of peri-tubular capillaries in normal
kidney tissue, however diffuse and brightening positive
linear deposits of C4d of 50% peri-tubular capillaries in
AMR. The deposit of C4d in 50% peri-tubular capillaries
endothelial cells and basal membrane was significant
morphological dis- orders of complement activation in
AMR (Figures 9, 10, 11).The correlation between Scr and renal fibrosis
Scr was increasing with the aggravation of renal fibrosis in
patients (Table 1). It was shown by the statistic analysis
with Spearman rank correlation coefficience that there was
negative correlation between Scr and the expression level
of MMP-2 in renal allograft tissue (r = -0.077, P = 0.556
>0.05), however there were positive correlation between
Scr in serum and expression level of TIMP-1 in renal allo-
graft tissue (r = 0.718, P = 0.000<0.05).Figure 1 MMP-2 expression in renal tissue with different
degree of inflammatory infiltration(EnVision assay; original
magnification × 200). Control group.Discussion
Renal transplantation is the best therapy for end stage
renal failure. It improves life quality and survival time
of recipients compared to other therapies such as
hemodialysis. In the past decades,with the increasing
use of new kinds of immuno-suppressants and improv-
ment of HLA matching, the incidence of early acute re-
jection in renal transplantation decreased significantly,
while long-term renal graft survival remain to improve.
AMR is a main immune cause of long-term renal graft
survival. The histopathological changes of renal allograft
morphologically appear as renal interstitial fibrosis,
tubular atrophy and thickening of glomerular basement
membrane; and/or diffuse mononuclear cell infiltration
and fibrosis in interstitium; partial tubular atrophy,
lumen expansion, arrange irregularly, thickening ofFigure 3 MMP-2 expression in renal tissue with different
degree of inflammatory infiltration(EnVision assay; original
magnification × 200). IF/TA-II Group.
Figure 4 MMP-2 expression in renal tissue with different
degree of inflammatory infiltration(EnVision assay; original
magnification × 200). IF/TA-III Group.
Figure 6 TIMP-1 expressions in renal tissue with different
degree of interstitial fibrosis/tubular atrophy. (EnVision assay;
original magnification × 200). IF/TA-I Group.
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kidney allograft, common protein casts; focal and seg-
mental glomerulosclerosis, even if thoroughly hyaline
arteriolosclosis, mesangial region broading, chickening
of basement membrane, visible tram line shadow
(Figure 2C), arterial wall intima proliferation, narrowing
of artery, the intimal concentric and fibrous prolifera-
tion, stricture or blocking of lumen of interlobular artery
or its branches (Figure 2B). The clinical manifestations
were slowly creeping upward of serum creatinine, pro-
teinuria and hypertention, eventually developing into
ESRD, due to mesangial matrix sediment, thickening of
glomerular basement membrane and renal interstitial fi-
brosis or tubular atrophy. The pathological chages
involved into the disorder of ECM synthesis and breakFigure 5 TIMP-1 expressions in renal tissue with different
degree of interstitial fibrosis/tubular atrophy. (EnVision assay;
original magnification × 200). Control Group.down. The synthesis of ECM was influenced by TGF
and other cytokines, and the breakdown of ECM was
influenced by MMPs and TIMPs.
MMPs, also called as collagenase IV or collagenase A,
belong to one group of Zn dependent proteinases lead-
ing specific degradation of ECM, and one of their pri-
mary functions is to break down collagen IV. Collagen
IV is the main constituent in glomerular basement
membrane. MMP-2 with relative molecule weight
72,000, a kind of collagenase A, may degrade collagen
IV [3]. The disorder of MMP-2 expression might induce
changes in tubular basement membrane structure, thus
resulting to renal tubular epithelial cell transdifferentia-
tion with tubular atrophy, fibrosis and renal dysfunction
[4]. MMP-2 participates in the degradation of ECM,Figure 7 TIMP-1 expressions in renal tissue with different
degree of interstitial fibrosis/tubular atrophy. (EnVision assay;
original magnification × 200). IF/TA-II Group.
Figure 8 TIMP-1 expressions in renal tissue with different
degree of interstitial fibrosis/tubular atrophy. (EnVision assay;
original magnification × 200). IF/TA-III Group.
Figure 9 Expression of C4d and renal histology. C4d diffuse
staining in glomerular and peritubular capillaries(EnVision assay;
original magnification × 200).
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TIMP-1 play important roles in regulating the synthesis
and degradation of ECM.
The results of our present study suggested that MMP-
2 and TIMP-1 were weakly expressed in normal kidney
tissue, but their expression was upregulated in AMR.
MMP-2 was mainly expressed in IF/TA-I group, and its
expression was decreasing along with the aggravation of
pathological classification, however the expression of
TIMP-1 was increasing along with the aggravation of the
pathological classification of IF/TA, simultaneously renal
function was gradually aggravated and the level of Scr
was increasing along with the pathological classification
of IF/TA. The imbalance between MMP-2 and TIMP-1
might participate in the development of renal allograft
fibrosis, so it is necessary to explore the mechanism how
the imbalance between MMP-2 and TIMP-1 participates
in renal interstitial fibrosis and tubular atrophy of AMR.
It was reported in literature that the expression of
MMP-2 was decreased by 25mmol/L glucose, but the
expression of TIMP-2, the special inhibitor of TIMP-1,
was upregulated, which promoted ECM sidiment in theTable 1 Expression of MMP-2 and TIMP-1 in the renal
tissue and serum creatinine in groups with different
degrees of interstitial fibrosis and tubular atrophy and
normal controls (Mean ± SD)
Groups N MMP-2 (%) TIMP-1 (%) Scrum (umol/L)
Normal
controls
15 8.10 ± 4.41 9.02 ± 5.64 87.32 ± 2.38
IF/TA-I 16 39.52 ± 8.91※ 22.21 ± 12.62※ 175.81 ± 41.53※
IF/TA-II 14 23.85 ± 5.25※▲ 36.38 ± 13.12※▲ 327.07 ± 102.14※▲
IF/TA-III 16 15.55 ± 4.16※▲◆ 51.58 ± 12.75※▲◆ 535.42 ± 123.20※▲◆
※:P<0.05, vs Control Group; ▲:P<0.05, vs IF/TA-IGroup; ◆:P<0.05. vs
IF/TA-IIGroup.cultured human glomerular epithelial cells [5]. Berthier
CC et al [6] found that the expression of MMP-2 and its
inhibitor TIMP-2 and mRNA of TGF increased signifi-
cantly in chronic rejection animal model of Fisher and
Lewis mouse. Experiment on unilateral ureteral obstruc-
tion model based on TIMP-1 transgenic mice found that
the expression of TIMP-1 was upregulated, gelatinase ac-
tivity was downregulated, ICAM-1 and TGF, collage-
nIand III were upregulated, renal interstitial fibrosis and
macrophage infiltration aggravated, which suggest that
TIMP-1 over expression might paiticipate in renal inter-
stitial fibrosis and involve in the course of inflammatory
reaction [7]. Wagrowska- Danilewicz et al [8] found that
the expression of both MMP-2 and TIMP-1 were upre-
gulated in reanal allografts of 17 chronic allograft
nephropathy patients compared to renal tissue of 11 nor-
mal controls, which suggest the remodeling of impairedFigure 10 Expression of C4d and renal histology. Interstitial
fibrosis/tubular atrophy (HE staining,original magnification × 200).
Figure 11 Expression of C4d and renal histology. Glomerular
double contours (original magnification × 400).
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balance of MMP-2 and TIMP-1. The expression of
TIMP-1 was downregulated, while the mRNA and pro-
tein expression and activities of MMP-2 and MMP-9
were enhanced after treatment with benazapril and all-
trans retinoic acid (ATRA) in Wistar rat model of glom-
erular sclerosis compared to normal group [9]. The
results of above studies suggest the ATRA exerts protec-
tion role by downregulate the expression of TIMP-1 and
upregulate the mRNA expression and activity of MMP-2
and MMP-9, regulate the balance of the ratio of MMPs
and TIMPs, and thus decrease ECM sediment. However
it remains a question which needs further study that how
to inhibit the activity of TGF, keep the balance of the ac-
tivities of MMPs and TIMPs, retard ECM over sediment
and improve renal allograft function.
If further researches may determine the pathogenesis
of how the imbalance of MMP-2/TIMP-1 participates in
AMR, then it might be the target of avoiding chronic
renal allograft dysfunction to regulate the expression
and activities of MMP-2 and TIMP-1.
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